June 29, 2021 – Echocardiography with ultrasound enhancing agents (UEAs) has proven to be a valuable imaging procedure after surgery for children born with single ventricle congenital heart disease (CHD). This heart defect occurs when one of the two ventricles is not large enough or strong enough to work correctly.

June 29, 2021 – The virtual exhibit hall at American Society of Echocardiography (ASE) 2021 Scientific Sessions Virtual Experience featured more than 30 companies and organizations highlighting the latest vendor technology and other services.

June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare transcatheter valve-in-valve procedure using a Sapien 3 transcatheter aortic valve. 

June 29, 2021 - ScImage Inc.has partnered with National Cardiovascular Management (NCM), a national consulting and management company that partners with entrepreneurial physicians to design and develop state-of-the-art outpatient cath lab facilities. 

CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.

June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural heart procedure in the world using 4-D hologram technology developed by EchoPixel. 

June 28, 2021 — Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd. entered into a multi-year partnership that leverages the companies' synergies in cardiac artificial intelligence (AI) and data analytics.

June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19 initially treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. The research was part of the Overcoming COVID-19 Study, a nationwide collaboration of physicians at pediatric hospitals and the Centers for Disease Control and Prevention (CDC). 

June 28, 2021 — The U.S. Food and Drug Administration (FDA) announced June 25 it has added a warning on the Moderna and Pfizer COVID-19 messenger RNA (mRNA) vaccine fact sheets to explain they may cause myocarditis in rare cases as a side effect. The agency said the side effect is very rare and patients generally recover quickly, but it can disportionally affect younger patients in their teens and early 20s. 

June 25, 2021 – COVID-19 changed everything in healthcare, and a benefit from this pandemic was a surge in innovations in the medical field. One of these is the growth in artificial intelligence (AI) guided medical care.

A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).

A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now